Raptiva Lawsuits - Raptiva Lawyer - Raptiva Attorney - Raptiva Side Effects - PML- Progressive Multifocal Leukoencephalopathy - Efalizumab Lawyer |
Raptiva Free Case Evaluation |
|
|---|---|---|
Raptiva Side Effects Lawsuit : Progressive Multifocal Leukoencephalopathy (PML). |
||
 |
Raptiva Medication:
Raptiva (efalizumab) is a subcutaneous injection administered once a week to
treat psoriasis. The drug is a therapeutic antibody designed to block the
activation of special immune cells called T-cells. Overactivity of T-cells leads
to excess skin cells being produced, which build up in the form of plaques,
causing the skin disease psoriasis. However, by suppressing the body’s natural defense system, Raptiva has also been associated with meningitis, immune-mediated hemolytic
anemia, and other life-threatening infections.
Generic Name: Efalizumab
Brand Name: Raptiva
Manufacturer: Genentech
Progressive Multifocal Leukoencephalopathy (PML):
Progressive multifocal leukoencephalopathy (PML), is a rare and usually fatal viral disease that is characterized by progressive damage or inflammation of the white matter of the brain at multiple locations (multifocal). It usually is found exclusively in people with severe immune system deficiency, e.g. transplant patients on immunosuppressive medications, or AIDS patients. Raptiva suppresses the body’s natural defense system and can also increase the risk of serious infections, PML, and cancer.
FDA Issues Black Box Warning for Raptiva:
On October 16, 2008 the FDA announced labeling changes for Raptiva including a
black box warning--the strongest warning a drug can receive--regarding the risk
of serious, life-threatening infections, including bacterial sepsis, viral
meningitis, invasive fungal disease, progressive multifocal leukencephalopathy
(PML) and other opportunistic infections.
Though not approved for children under the age of 18, the label also includes data from juvenile animal studies in mice (age equivalent between 1 and 14 years old) indicating a potential risk for permanent suppression of the immune system with repeat administration of Raptiva in this age group.
On December 12, 2008 Health Canada also issued a warning regarding the risk of serious infections, including PML, in patients treated with Raptiva.
On February 19, 2009 The FDA issued a Public Health Advisory to notify healthcare professionals of three
confirmed, and one possible report of progressive multifocal leukoencephalopathy
(PML), a rare brain infection, in patients using the psoriasis drug Raptiva.
Raptiva Withdrawn From U.S. Market Due To PML Risks:
On April 8, 2009 Genentech and FDA notified healthcare professionals of the voluntary, phased withdrawal of Raptiva, a medication for treatment of psoriasis, from the U.S. market due to a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML). By June 8, 2009, Raptiva will no longer be available in the United States. Prescribers are being asked not to initiate Raptiva treatment for any new patients. Prescribers should immediately begin discussing with patients currently using Raptiva how to transition to alternative therapies. The FDA strongly recommends that patients work with their health care professional to transition to alternative therapies for psoriasis.
Signs and symptoms of Progressive Multifocal Leukoencephalopathy (PML) :
· Confusion
· Dizziness
· Progressive weakness
· Loss of balance or coordination
· Difficulty talking or walking
· Visual impairment
· Partial paralysis
· Seizures
Raptiva Lawsuit News Archive >>>
If you or a loved one have experienced Raptiva Side Effects such as progressive multifocal Leukoencephalopathy (PML) you may be entitled to compensation. Contact the Raptiva Lawyers of Ennis & Ennis, P.A. today about a potential Raptiva Side Effects Lawsuit. Our experienced attorneys can answer any questions you may have about Raptiva side effects, a potential Raptiva class action lawsuit, or PML.
